A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
This Study is
No Longer Enrolling
Adult
- pathologically confirmed biliary tract cancer, including IHC, EHC, and GBC - must have received at least 1 prior line of systemic therapy, and received no more than 2 prior lines of therapy in the metastatic setting (disease recurrence < 6 months from the last dose of adjuvant therapy in resected patients will be considered the first line of therapy) - patients with the following prior treatments are excluded / not eligible: - anti-CTLA-4, anti-PD-1, or anti-PD-L1or other immune checkpoint inhibitor therapeutic antibodies or pathway-targeting agents; - MEK or ERK inhibitors - patients with active, untreated brain mets will are not eligible
Treatment
Outpatient CTRC
University of Colorado Hospital
Protocol Number: 22-0030
More information available at ClinicalTrials.gov: NCT04941287
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers